Mannkind Stock Price, News & Analysis

MannKind (Nasdaq: MNKD) announced positive 30-week results from its Phase 4 INHALE-3 study for Afrezza®, an inhaled insulin for type 1 diabetes. The study showed that more adults achieved target A1c levels (<7%) when switching to or remaining on Afrezza plus basal insulin, compared to usual care (multiple daily injections or insulin pumps).

Key findings include:

• 100% increase in subjects achieving A1c <7% at 30 weeks in the Afrezza-treated group from baseline
• More than double the subjects achieved A1c <7% at week 30 after switching from usual care to Afrezza at week 17

The company plans to present detailed results at upcoming conferences, including ATTD in March and additional events in 2025.

MannKind (Nasdaq: MNKD) has received clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to initiate the Phase 3 clinical trial (ICoN-1) of Clofazimine Inhalation Suspension for treating nontuberculous mycobacterial (NTM) lung disease. The global study is now cleared in four countries: U.S., Japan, South Korea, and Australia, with Taiwan expected in Q4 2024. The first U.S. patient has been randomized.

The ICoN-1 study aims to enroll approximately 230 eligible participants across more than 100 sites globally, ensuring at least 180 participants are evaluable for efficacy. Dr. Kozo Morimoto, lead principal investigator for ICoN-1 in Japan, emphasized the importance of developing potential therapies for the rising number of NTM lung infections in Japan and globally.

MannKind (Nasdaq: MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. Chief Financial Officer Chris Prentiss and Dr. Wasim Fares, Therapeutic Area Head for Orphan Lung Diseases, will present during a fireside chat on Wednesday, September 18 at 1:20 p.m. Eastern Time.

The presentation will be accessible via a live audio webcast on MannKind's website, with a recorded version available for approximately 30 days after the event. This conference provides an opportunity for MannKind to share updates on their innovative therapeutic products and connect with healthcare industry professionals.

MannKind (Nasdaq: MNKD), a company developing inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:

• 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 11:00 a.m. ET
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 6 at 7:00 a.m. ET
• H.C. Wainwright 26th Annual Global Investment Conference in New York on September 10 at 9:30 a.m. ET

Live audio webcasts will be available on MannKind's website, with recordings accessible for about 30 days after each conference.

MannKind (Nasdaq: MNKD) has announced significant changes to its Board of Directors. Kent Kresa, who has served on the board since June 2004 and was Chairman from 2016 to 2020, will retire effective September 30, 2024. He will continue as Chairman Emeritus. Steven B. Binder, the company's former Chief Financial Officer, will join the board on the same date.

Binder, who served as CFO from July 2017 to April 2024, is currently Executive Vice President of Special Projects. He will step down from this role when he joins the board. James S. Shannon, current Chairman, praised Kresa's two decades of leadership and expressed enthusiasm for Binder's appointment, citing his financial stewardship and role in diversifying MannKind's revenue streams. The board will maintain nine members following these changes.

MannKind (MNKD) reported strong financial results for Q2 2024, with total revenues of $72M, up 49% year-over-year. The company achieved its ninth consecutive quarter of revenue growth, approaching an annual revenue run rate of over $275 million. Key highlights include:

- Royalties from Tyvaso DPI increased 34% to $25.6M
- Collaborations and services revenue up 132% to $26M
- Afrezza net revenue grew 20% to $16.3M
- YTD 2024 net income of $9M; Non-GAAP net income of $29M

MannKind also made progress on its clinical pipeline, initiating Phase 3 trials for MNKD-101 and Phase 1 trials for MNKD-201. The company remains focused on its diversification strategy, allocating capital towards pipeline development, in-line growth, and debt reduction.

MannKind (Nasdaq: MNKD) has launched an educational website, LearnAboutNTM.com, to raise awareness of nontuberculous mycobacterial (NTM) lung disease. The launch coincides with World NTM Awareness Day on August 4. NTM lung disease is a rare condition caused by naturally occurring bacteria that can lead to serious lung damage in susceptible individuals.

Key points:

• NTM affects nearly 100,000 people in the U.S. and over 150,000 in Japan
• Prevalence is increasing globally, with a 7.5% annual rise in the U.S.
• The disease is more common in women over 65
• MAC (mycobacterium avium complex) accounts for 80% of NTM cases in the U.S.
• 15-20% of NTM patients are refractory to treatment

The website aims to promote early detection and provide resources for patients and caregivers.

MannKind (Nasdaq: MNKD) has announced that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024, before the market opens. The company will issue a press release detailing the quarterly results approximately one hour before hosting a webcast at 9:00 a.m. Eastern Time.

The webcast, accessible to investors, media, and the general public, will feature CEO Michael Castagna and CFO Chris Prentiss. Interested parties can access the webcast through MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours after the call and remain accessible for about 90 days.

MannKind (Nasdaq: MNKD) announced positive results from its INHALE-3 Phase 4 clinical trial, comparing inhaled insulin Afrezza with usual care for adults with Type 1 Diabetes (T1D). The 17-week study, presented at the American Diabetes Association's 84th Scientific Sessions, met its primary efficacy endpoint, showing non-inferior HbA1c levels with inhaled insulin. Key findings include 30% of the Afrezza group achieving HbA1c <7% versus 17% in the usual care group, and 24% reaching >70% Time-in-Range (TIR) with no increased hypoglycemia. Over 50% expressed interest in continuing Afrezza. The study supports inhaled insulin as a viable T1D treatment option.